Privately-held US biotech company ImaginAb has had what it has describes as ‘a transformational year’ in an update on its achievements over the year.
The Californian firm is developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent as well as therapeutic radiopharmaceuticals (RPT), and has made significant progress on both fronts in the past 12 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze